Modulating cholesterol efflux capacity to improve cardiovascular disease

Nicholas Brownell, Anand Rohatgi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Low HDL-cholesterol (HDL-C) levels are predictive of incident atherosclerotic cardiovascular disease events. However, the use of medication to raise HDL-C levels has not consistently shown clinical benefit. As a result, studies have shifted toward HDL function, specifically cholesterol efflux, which has been inversely associated with prevalent subclinical atherosclerosis as well as subsequent atherosclerotic cardiovascular disease events. The purpose of this review is to summarize the effects of current medications and interventions on cholesterol efflux capacity. RECENT FINDINGS: Medications for cardiovascular health, including statins, fibrates, niacin, and novel therapeutics, are reviewed for their effect on cholesterol efflux. Differences in population studied and assay used are addressed appropriately. Lifestyle interventions, including diet and exercise, are also included in the review. SUMMARY: The modification of cholesterol efflux capacity (CEC) by current medications and interventions has been investigated in both large randomized control trials and smaller observational cohorts. This review serves to compile the results of these studies and evaluate CEC modulation by commonly used medications. Altering CEC could be a novel therapeutic approach to improving cardiovascular risk profiles.

Original languageEnglish (US)
JournalCurrent Opinion in Lipidology
DOIs
StateAccepted/In press - May 20 2016

Fingerprint

Cardiovascular Diseases
Cholesterol
HDL Cholesterol
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Niacin
Life Style
Atherosclerosis
Diet
Health
Therapeutics
Population

ASJC Scopus subject areas

  • Cell Biology
  • Genetics
  • Molecular Biology
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Modulating cholesterol efflux capacity to improve cardiovascular disease. / Brownell, Nicholas; Rohatgi, Anand.

In: Current Opinion in Lipidology, 20.05.2016.

Research output: Contribution to journalArticle

@article{5f0665b07b314490bfc12e0c9c12736c,
title = "Modulating cholesterol efflux capacity to improve cardiovascular disease",
abstract = "PURPOSE OF REVIEW: Low HDL-cholesterol (HDL-C) levels are predictive of incident atherosclerotic cardiovascular disease events. However, the use of medication to raise HDL-C levels has not consistently shown clinical benefit. As a result, studies have shifted toward HDL function, specifically cholesterol efflux, which has been inversely associated with prevalent subclinical atherosclerosis as well as subsequent atherosclerotic cardiovascular disease events. The purpose of this review is to summarize the effects of current medications and interventions on cholesterol efflux capacity. RECENT FINDINGS: Medications for cardiovascular health, including statins, fibrates, niacin, and novel therapeutics, are reviewed for their effect on cholesterol efflux. Differences in population studied and assay used are addressed appropriately. Lifestyle interventions, including diet and exercise, are also included in the review. SUMMARY: The modification of cholesterol efflux capacity (CEC) by current medications and interventions has been investigated in both large randomized control trials and smaller observational cohorts. This review serves to compile the results of these studies and evaluate CEC modulation by commonly used medications. Altering CEC could be a novel therapeutic approach to improving cardiovascular risk profiles.",
author = "Nicholas Brownell and Anand Rohatgi",
year = "2016",
month = "5",
day = "20",
doi = "10.1097/MOL.0000000000000317",
language = "English (US)",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Modulating cholesterol efflux capacity to improve cardiovascular disease

AU - Brownell, Nicholas

AU - Rohatgi, Anand

PY - 2016/5/20

Y1 - 2016/5/20

N2 - PURPOSE OF REVIEW: Low HDL-cholesterol (HDL-C) levels are predictive of incident atherosclerotic cardiovascular disease events. However, the use of medication to raise HDL-C levels has not consistently shown clinical benefit. As a result, studies have shifted toward HDL function, specifically cholesterol efflux, which has been inversely associated with prevalent subclinical atherosclerosis as well as subsequent atherosclerotic cardiovascular disease events. The purpose of this review is to summarize the effects of current medications and interventions on cholesterol efflux capacity. RECENT FINDINGS: Medications for cardiovascular health, including statins, fibrates, niacin, and novel therapeutics, are reviewed for their effect on cholesterol efflux. Differences in population studied and assay used are addressed appropriately. Lifestyle interventions, including diet and exercise, are also included in the review. SUMMARY: The modification of cholesterol efflux capacity (CEC) by current medications and interventions has been investigated in both large randomized control trials and smaller observational cohorts. This review serves to compile the results of these studies and evaluate CEC modulation by commonly used medications. Altering CEC could be a novel therapeutic approach to improving cardiovascular risk profiles.

AB - PURPOSE OF REVIEW: Low HDL-cholesterol (HDL-C) levels are predictive of incident atherosclerotic cardiovascular disease events. However, the use of medication to raise HDL-C levels has not consistently shown clinical benefit. As a result, studies have shifted toward HDL function, specifically cholesterol efflux, which has been inversely associated with prevalent subclinical atherosclerosis as well as subsequent atherosclerotic cardiovascular disease events. The purpose of this review is to summarize the effects of current medications and interventions on cholesterol efflux capacity. RECENT FINDINGS: Medications for cardiovascular health, including statins, fibrates, niacin, and novel therapeutics, are reviewed for their effect on cholesterol efflux. Differences in population studied and assay used are addressed appropriately. Lifestyle interventions, including diet and exercise, are also included in the review. SUMMARY: The modification of cholesterol efflux capacity (CEC) by current medications and interventions has been investigated in both large randomized control trials and smaller observational cohorts. This review serves to compile the results of these studies and evaluate CEC modulation by commonly used medications. Altering CEC could be a novel therapeutic approach to improving cardiovascular risk profiles.

UR - http://www.scopus.com/inward/record.url?scp=84969786592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969786592&partnerID=8YFLogxK

U2 - 10.1097/MOL.0000000000000317

DO - 10.1097/MOL.0000000000000317

M3 - Article

C2 - 27213627

AN - SCOPUS:84969786592

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

ER -